Diagnostic and Interventional Cardiology

Myocarditis (inflammation of the heart muscle) is usually caused by viruses, such as in Covid-19 disease. However, it can also be induced by medication, toxic substances or in the context of a rheumatological disease.

AI Enables Personalized Treatment of Myocarditis

April 6, 2022 – Myocarditis (inflammation of the heart muscle) is usually caused by viruses, such as in Covid-19 disease ...

April 06, 2022

News | Coronavirus (COVID-19)

NIH Awards $437,000 to Study Effects of COVID on Aortic Valve

April 6, 2022 – The National Institute of Health awarded $436,642 to associate professor of biomedical engineering ...

April 06, 2022

Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.

News | Pacemakers

Abbott Receives FDA Approval for Aveir VR Leadless Pacemaker System

April 5, 2022 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber ...

April 05, 2022

Sponsored Content

Feature | Nuclear Imaging

Cardiac PET/CT — A New Standard for Cardiac Imaging

Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...

November 12, 2025

GE Healthcare and AliveCor have announced a partnership to deliver medical-grade six-lead electrocardiograms (ECGs) taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting – at home or on the go – directly into GE Healthcare’s MUSE Cardiac Management System for physicians to view and evaluate.

News | ECG

GE Healthcare and AliveCor Integrate Data from ECGs Into Clinical Workflow

April 4, 2022 – GE Healthcare and AliveCor have announced a partnership to deliver medical-grade six-lead ...

April 04, 2022

The American College of Cardiology's Evolving Practice of Cardiovascular Precision Medicine course on May 13, 2022 will feature an opening session that includes Geoffrey Ginsburg, MD, PhD and Joshua C. Denny, MD, MS.

News | Cardiovascular Education

ACC Course Provides Updates from NIH's All of Us Research Program

April 4, 2022 – The American College of Cardiology's Evolving Practice of Cardiovascular Precision Medicine course on ...

April 04, 2022

A stroke patient performing upper limb robotic therapy

News | Stroke

Researchers Examine Impact of Robotic Assistance Level in the Upper Limb Rehabilitation of Stroke Survivors

April 4, 2022 – Researches at the Department of Occupational Therapy, College of Health and Human Sciences, Osaka ...

April 04, 2022

Sponsored Content

Feature

Intuitive Imaging Workflow System Offers Improved Efficiency, Flexibility

SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...

June 17, 2025

Keck Medicine of USC has launched its COVID Recovery Clinic, a multidisciplinary program led by a core team of clinicians specializing in primary care, pulmonology and physical therapy.

News | Coronavirus (COVID-19)

Keck Medicine of USC Launches COVID Recovery Clinic to Treat Patients with Long COVID-19

April 4, 2022 – Keck Medicine of USC has launched its COVID Recovery Clinic, a multidisciplinary program led by a core ...

April 04, 2022

Staying well-hydrated may be associated with a reduced risk for developing heart failure, according to researchers at the National Institutes of Health.

News | Heart Failure

Good Hydration May Reduce Long-term Risks for Heart Failure

April 4, 2022 – Staying well-hydrated may be associated with a reduced risk for developing heart failure, according to ...

April 04, 2022

Observational research has suggested that light alcohol consumption may provide heart-related health benefits, but in a large study published in JAMA Network Open, alcohol intake at all levels was linked with higher risks of cardiovascular disease.

News | Heart Failure

Large Study Challenges Theory that Light Alcohol Consumption Benefits Heart Health

April 4, 2022 – Observational research has suggested that light alcohol consumption may provide heart-related health ...

April 04, 2022

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

But scientists at the Medical College of Georgia and Georgia State University also say that the chronic high-salt diet most Americans consume can turn this system against us, resulting in hyperactivity of these neurons, continuing production of this hormone vasopressin, constriction of blood vessels and increasing our risk for common cardiometabolic diseases like high blood pressure and heart disease.

News | Heart Failure

New Clues About How A High-Salt Diet Contributes to Cardiometabolic Diseases Found Deep in the Brain

April 4, 2022 – Deep in the brain a group of large neurons produce a hormone which prompts our bodies to hold onto more ...

April 04, 2022

$Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first patient has been enrolled in the quadruple-blinded sham-controlled AIM HIGHer IDE clinical study (Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction) evaluating CCM therapy for patients who have left ventricular ejection fraction ranging between 40% and 60% inclusive. The study will be conducted across approximately 150 cente$

News | Heart Failure

Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer Study

April 4, 2022 – Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart ...

April 04, 2022

News | ACC

Esperion Announces Two NEXLETOL Data Presentations at ACC.22

April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...

April 04, 2022

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Significant VHD is commonly encountered in practice, more commonly with advancing age, among women, and identified more frequently in centers offering percutaneous mitral therapies.

News | ACC

egnite, Inc. Announces Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the US

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

April 03, 2022

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

News | ACC

ACC22: Interim Findings Show Promise in Decreasing Shortness of Breath From Hypertrophic Cardiomyopathy

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

April 03, 2022

Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial

News | Heart Failure

Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at ACC22

April 3, 2022 — Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ...

April 03, 2022